Health Minister Khaled Abdel Ghaffar’s July decree explicitly exempting seven therapeutic drug derivatives, including Parkinson’s medications, from the restricted narcotics list came into effect Monday upon its publication in the Official Gazette.
The signed July 20 measure comes after a previous ministerial order restructuring drug schedules unintentionally swept common medical treatments into the same classification as controlled narcotics, creating legal uncertainty for healthcare providers and patients.
The ministry’s decree clarifies item 12 of Narcotics Schedule 1 (full spectrum restriction). It explicitly removes seven pharmaceutical derivatives: venlafaxine, desvenlafaxine, carbidopa, levodopa, foscarbidopa, melevodopa, and foslevodopa.
A senior official at the Egyptian Drug Authority, speaking to Al Manassa on condition of anonymity, said the earlier February decree aimed at reorganizing drug schedules had broadly listed the “phenethylamine” chemical group without detailing all its derivatives.
Because only common variants were specified, broad interpretations left room for non-abusive, therapeutic medications to be wrongly categorized as illegal substances.
The newly exempted compounds include key treatments for Parkinson’s disease, such as levodopa and carbidopa, as well as widely prescribed antidepressants. The official emphasized that these medications have no history or potential for recreational abuse.
The amendment follows findings from the Forensic Medicine Authority and relevant regulatory bodies, which warned that while these compounds chemically derive from phenethylamine, they remain legitimate medicines rather than illicit narcotics.
The specialized committee on narcotics schedules subsequently recommended their explicit exclusion to ensure patients carrying valid prescriptions are not subjected to criminal prosecution or accused of drug possession, the source explained to Al Manassa.
In the same decree, the ministry added several raw chemical compounds to Narcotics Schedule 3 (raw material tracking). These include amyl nitrite, isoamyl nitrite, isopropyl nitrite, isobutyl nitrite, and cannabidiol.
The official distinguished between exempting finished drug derivatives and restricting raw materials, noting that the newly added Schedule 3 compounds carry a high risk of illicit diversion.
Certain nitrite compounds can be repurposed for manufacturing explosives, while cannabidiol in raw forms, such as oils, can be abused as an alternative intoxicant.
Schedule 1 restrictions automatically cover raw materials, formulations, end products, and derivatives under strict legal penalties. By contrast, Schedule 3 focuses on regulating specific raw materials to oversee their commercial circulation without automatically criminalizing the final pharmaceutical products.
The regulatory chain reaction began in February when the Supreme Constitutional Court struck down previous rulings by the head of the Egyptian Drug Authority that altered drug schedules.
The court ruled that updating narcotics schedules is an exclusive authority of the health minister. To remedy the legal vacuum created by the ruling, the health minister issued a decree replacing the schedules attached to the Anti-Narcotics Law, formally reasserting ministerial jurisdiction over controlled substances.
